Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,117 across all filing types
Latest filing 2020-04-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于续聘公司2020年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the company's audit firm for the fiscal year 2020. It details the qualifications, experience, and independence of the audit firm, as well as the approval process by the board, audit committee, independent directors, and supervisory board. The document does not contain any financial statements or audit reports themselves, but rather the decision and rationale for continuing the audit engagement. The document length is 3633 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information (AR) type, as it relates specifically to audit firm appointment and audit-related information, but is not a full annual report or audit report itself. It is not a Regulatory Filing (RNS) because it is a substantive announcement about audit firm reappointment, not a mere certification or attestation. Confidence is high due to clear audit-related content and procedural details. FY 2020
2020-04-28 Chinese
2020年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "珠海赛隆药业股份有限公司 2020 年第一季度报告全文" which translates to "Zhuhai Sailong Pharmaceutical Co., Ltd. 2020 First Quarter Report Full Text." It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2020. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2020
2020-04-28 Chinese
2020年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 First Quarter Report" of Zhuhai Sailong Pharmaceutical Co., Ltd. It contains detailed financial data such as revenue, net profit, cash flow, and shareholder information for the first quarter of 2020. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is over 6000 characters and contains substantive financial data, so it is not a mere announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2020
2020-04-28 Chinese
2019年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2019 by Zhuhai Sailong Pharmaceutical Co., Ltd. It contains detailed descriptions of the company's internal control environment, risk assessment, control activities, information and communication, and evaluation conclusions. The document includes specific internal control defect standards and concludes on the effectiveness of internal controls. It is a comprehensive report focused on internal control evaluation rather than a general annual report or audit report. The content aligns with an Audit Report / Information (AR) category, as it is a standalone report on internal control evaluation and does not constitute a full annual report or financial statements. The document length (7435 characters) supports it being a full report rather than a brief announcement. Therefore, the appropriate classification is AR with high confidence. FY 2019
2020-04-28 Chinese
2019年年度审计报告
Regulatory Filings
2020-04-28 Chinese
内部控制规则落实自查表
Regulatory Filings Classification · 95% confidence The document is titled '内部控制规则落实自查表' which translates to 'Internal Control Rules Implementation Self-Inspection Form'. It contains detailed internal control checklists related to audit committee operations, information disclosure, insider trading controls, fundraising, related party transactions, guarantees, major investments, and other important matters. The document is a self-assessment or internal control checklist rather than a financial report or announcement. It does not contain financial statements, earnings data, or regulatory certifications. It is not an announcement of a report but a detailed internal control compliance document. This type of document fits best under Regulatory Filings (RNS) as it is a compliance-related filing that does not fit into other specific categories like Annual Report, Audit Report, or Management Reports.
2020-04-28 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.